Partnership Landscape - May 2025

DP and CP Partnerships (2020+)

Notes: 

1. Company size corresponds with number of partnerships, link thickness corresponds with recency of the partnership (thicker lines are more recent; partnerships for which a year could not be established are set at minimum thickness). 

2. Partnership activity was pulled from company websites and press releases and is based on publicly available information. Research collaborations that have resulted in pubs / conference abstracts but that have not been publicized as partnerships may not be included. Only includes partnerships announced 2020-2025

3. Many companies have offerings spanning multiple product categories; the primary or most comprehensive product offering was used for node shading.

4. Incubators, accelerators, research groups, and investors were excluded.

5. There are additional pathology companies that have been excluded because they do not have digital pathology offerings. Partnerships with companies that are unrelated to digital pathology have been excluded

‍

‍

‍

It’s been about eight months since we last explored the partnership landscape in digital and computational pathology—and the pace hasn’t slowed. In just the first half of 2025, we've tracked over 40 new collaborations across the ecosystem.

‍

Most Active Vendor: PathAI

PathAI continues to lead in partnership activity, expanding the adoption of its AISight IMS platform across academic medical centers and reference labs. In parallel, PathAI has deepened its integration with third-party AI algorithms—underscoring their positioning as not just an algorithm developer, but a platform provider.

Honorable mentions go to Mindpeak, Pramana, Gestalt, Techcyte, Indica Labs, Visiopharm, Aiosyn, and AIRA Matrix, all of whom have announced multiple new partnerships this year.

‍

Busiest Pharma: AstraZeneca

AstraZeneca has emerged as the most active pharma partner in computational pathology, with seven collaborations since 2020—including four in the past year alone (Roche, Owkin, Lunit, Mindpeak). These partnerships span a range of use cases, cancer types, and development phases, reflecting AstraZeneca’s broad integration of digital pathology into its biomarker strategy.

‍

Top Theme: Integration & Interoperability

Nearly half of all 2025 partnerships so far have focused on improving integration—whether between AI algorithms, image management systems, scanners, or LIS platforms. While clinical and research implementation deals continue to grow, integration remains the most common partnership type.

‍

New Category: Digital Cytology

This year, we’ve added digital cytology to our partnership tracking. After being absent in past editions, companies in this space are increasingly forming collaborations with digital pathology vendors and other ecosystem players.

‍

First-time Partners to Watch

Several emerging players announced their first public partnerships in 2025, including:

• Pictor Labs
• DigitCells
• Biomy
• Primaa
  
  

Signs of Market Maturity

Beyond partnerships, other recent developments suggest a maturing market:

• AstraZeneca–Roche CDx collaboration for TROP2 QCS NMR
• Roche’s QCS tool granted Breakthrough Device Designation (BDD)
• Modella’s Pathchat AI also received BDD
• New funding rounds across many players including Proscia, Deciphex, OptraScan, MindPeak, Aignostics, Ataraxis, Gestalt, and PathPresenter
• Leica’s strategic investment in Indica Labs with CDx capabilities in mind
• IBEX’s FDA-clearance for their prostate cancer Dx AI tool
• Tempus partners with Imagene and ArteraAI to expand commercial reach of emerging LDT tools
  
  

As partnerships continue to drive access, deployment, and validation of digital pathology tools, we’ll be tracking these signals of market evolution closely.